INTERCEPT PHARMACEUTICALS INC 4
4 · INTERCEPT PHARMACEUTICALS INC · Filed Jul 7, 2015
Insider Transaction Report
Form 4
Adorini Luciano
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2015-07-01+649→ 10,709 total - Exercise/Conversion
Restricted Stock Units
2015-07-01−649→ 1,298 total→ Common Stock (649 underlying)
Footnotes (2)
- [F1]Conversion of restricted stock units ("RSUs") to shares of common stock on a one-to-one basis.
- [F2]On November 16, 2012, the reporting person was granted 10,384 RSUs. The RSUs reported as having been disposed and the corresponding shares reported as having been acquired, representing 6.25% of the shares underlying the RSUs, became vested on July 1, 2015, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). The remainder of the shares underlying the RSUs will vest pro rata on a quarterly basis from October 1, 2015 through January 1, 2016, subject to the terms and conditions of the award and the 2012 Plan.